Dysport abobotulinumtoxinA: Phase III data

Top-line data from a double-blind, international Phase III trial in 235 children with hemiparetic or diplegic cerebral palsy with lower limb spasticity showed that 10 and 15 U/kg/leg doses of Dysport each met the primary endpoint of improving muscle tone as measured by MAS scores at week 4 vs. placebo (p<0.05 for both). Dysport also met the secondary endpoint of improving PGA score vs. placebo. ...